Organization | Armauer Hansen Research Institute, Ethiopia

Armauer Hansen Research Institute, Ethiopia Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Addis Ababa Ethiopia (1970)

Organization Overview

First Clinical Trial

2005

NCT00994695

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Armauer Hansen Research Institue/AHRI/,Ethiopia | Armauer Hansen Research Institute, Ethiopia

Active Ingredients

Drugs in Phase 4 Trials (5)

albendazole (Albenza) (2 trials)

azithromycin (zithromax) (1 trial)

ivermectin (stromectol) (1 trial)

killed oral cholera vaccine (1 trial)

primaquine (1 trial)

Drugs in Phase 3 Trials (2)

cyclosporine (sandimmune) (4 trials)

prednisone (meticorten) (3 trials)

Drugs in Phase 2 Trials (2)

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi) (1 trial)

vitamin d3 (2 trials)

Drugs in Phase 1 Trials (2)

ag85b-esat-6 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 2)

Cholera (Phase 4)

Elephantiasis (Phase 4)

Elephantiasis, Filarial (Phase 4)

Erythema Nodosum (Phase 2)

Filariasis (Phase 4)

HIV Infections (Phase 2)

Leprosy (Phase 3)

Malaria (Phase 4)

Meningitis (Phase 2)

Meningitis, Meningococcal (Phase 2)

Trachoma (Phase 4)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 11